13 Most Undervalued NASDAQ Stocks To Buy According To Hedge Funds

9. Gilead Sciences, Inc. (NASDAQ:GILD)

Number of Hedge Fund Holders: 74

Forward P/E Ratio as of March 12: 14.86

Gilead Sciences, Inc. (NASDAQ:GILD), a biopharmaceutical company based in California, develops and markets treatments for virology, oncology, and other medical conditions across the US, Europe, and worldwide. On March 12, Gilead presented new data on its HIV treatment portfolio and research pipeline at the Conference on Retroviruses and Opportunistic Infections 2025. The findings highlight Gilead’s progress in advancing treatment options, improving patient outcomes, and working toward a potential cure for HIV. Gilead is among the most undervalued stocks to invest in.

Gilead Sciences, Inc. (NASDAQ:GILD) had a strong performance in both the fourth quarter and full year. In 2024, total product sales rose 8% year-over-year to $26.8 billion, with fourth quarter sales climbing 13% to $7.2 billion. HIV sales for the year reached $19.6 billion, exceeding Street expectations. Biktarvy, a leading HIV treatment, saw a 13% rise in sales. Gilead’s HIV business has demonstrated steady growth, with annual increases of 5% in 2022, 6% in 2023, and 8% in 2024, driven by innovation and strong execution. Gilead also returned $5.1 billion to shareholders last year, including $3.9 billion in dividends and $1.2 billion in share buybacks.

As per Insider Monkey’s fourth quarter database, 74 hedge funds were bullish on Gilead Sciences, Inc. (NASDAQ:GILD), an increase from 59 funds in the last quarter. Jim Simons’ Renaissance Technologies held the biggest position in the firm, with 5.3 million shares worth $492.3 million.